Opioids & Memory Loss After Surgery: New Research

Millions of older adults undergo surgery each year and are routinely given opioids to manage perioperative pain — yet a growing body of evidence suggests this combination may carry a hidden cognitive cost. A 2026 study published in Brain, Behavior, and Immunity by Muscat, Deems, Alvarez, and colleagues offers some of the most detailed mechanistic insight yet into why surgery combined with opioid use may lead to lasting memory problems in aging individuals — and, crucially, what might be done about it.

What This Study Found

Using an aged rat model designed to replicate clinical conditions — surgery followed by perioperative morphine administration — researchers investigated how the brain's hippocampus, a region critical to memory formation, responds at the cellular and molecular level following this combination of exposures.

The findings were striking. According to the study, memory impairments observed in the aged, surgery-plus-morphine group were not explained by systemic illness or broad neurodegeneration. Instead, researchers identified a cluster of highly specific changes:

• Synaptic instability: Animals showed selective reductions in dendritic spine subtypes associated with synaptic stability, along with impaired late-phase long-term potentiation (LTP) — a cellular process closely tied to learning and memory consolidation. Researchers also observed a blunted, experience-dependent upregulation of GluA1, a subunit of the AMPA receptor that plays a key role in synaptic plasticity.
• Axonal perturbation: Elevated circulating levels of neurofilament light chain (Nf-L), a biomarker of axonal injury, suggested sustained damage to nerve fibers persisting well beyond the surgical event.
• Hippocampal mitochondrial dysfunction: This emerged as the central finding. Surgery- and morphine-treated aged rats displayed impaired oxidative phosphorylation, reduced respiratory reserve capacity, and increased DNA oxidation specifically in hippocampal tissue. Importantly, these mitochondrial deficits were not observed in liver tissue, suggesting the dysfunction was not a body-wide metabolic problem but a brain-specific — and hippocampus-targeted — phenomenon.

The study also tested two therapeutic strategies. First, pharmacological inhibition of TLR4 signaling — a key mediator of neuroinflammation — administered at the time of surgery attenuated oxidative stress and partially restored mitochondrial function, implicating early neuroinflammatory signaling as a driver of long-term mitochondrial damage. Second, and perhaps most clinically exciting, targeted mitochondrial rejuvenation using the peptide SS-31, administered four weeks after surgery, robustly rescued hippocampal-dependent memory and normalized mitochondrial respiratory function — even in the presence of persistently elevated DNA oxidation and Nf-L levels.

It is important to note that these findings are derived from an animal model. Human clinical data will be necessary before these mechanisms or therapeutic strategies can be applied directly to patient care.

Clinical Significance

Postoperative cognitive dysfunction (POCD) is not a rare or minor problem. It is a well-documented complication disproportionately affecting older surgical patients, characterized by memory deficits, attention difficulties, and reduced processing speed that can persist for months or even years following an operation. Despite its prevalence, the underlying biology has remained poorly understood — a gap that has stymied efforts to develop targeted preventive or restorative treatments.

This research suggests that mitochondrial bioenergetics in the hippocampus may represent a key mechanistic substrate of POCD — at least in the context of opioid-accompanied surgery. By identifying a specific, measurable, and potentially reversible cellular target, the study opens the door to a new class of therapeutic interventions.

The role of SS-31 — also known as elamipretide — is particularly noteworthy. SS-31 is a mitochondria-targeting peptide that has been investigated across a range of conditions associated with mitochondrial dysfunction, including heart failure and age-related skeletal muscle decline. The study suggests that its ability to rescue memory and normalize mitochondrial respiration even weeks after the initial injury points toward a therapeutic window that extends beyond the immediate perioperative period. This is significant because it implies that patients who are already experiencing POCD may not have missed their opportunity for intervention.

The neuroinflammation data adds another layer of clinical relevance. The finding that blocking TLR4 signaling at the time of surgery partially protected mitochondrial function suggests that the inflammatory response triggered during surgery — amplified, the researchers suggest, by opioid exposure — may set off a cascade that ultimately impairs hippocampal energy metabolism. This positions neuroinflammation not just as a consequence of surgical stress, but as an upstream driver of long-term cognitive decline.

Current Access and Compliance Context

SS-31 (elamipretide) remains an investigational compound and is not currently approved by the FDA for any indication, including POCD. Research into its clinical applications is ongoing, with trials examining its potential in cardiac and mitochondrial disease contexts. Individuals interested in peptide-based therapies should seek care only from licensed, qualified medical providers operating within the bounds of applicable regulations.

The opioid crisis has already prompted many healthcare systems to adopt opioid-sparing surgical protocols, multimodal analgesia approaches, and enhanced recovery after surgery (ERAS) pathways. Research like this study adds a neurological dimension to that conversation — suggesting that the cognitive consequences of perioperative opioid use in older adults may be a compelling additional reason to minimize opioid exposure wherever clinically safe to do so. Any changes to perioperative pain management should only be made in close consultation with a patient's surgical and anesthesia team.

What Patients Should Know

If you or a loved one is an older adult preparing for surgery, or if you have experienced memory difficulties following a procedure, this research — while still in the animal model stage — raises important questions worth discussing with your healthcare provider.

Key takeaways from this study for informed patients include:

• Postoperative cognitive dysfunction is a recognized clinical phenomenon, and research is actively working to understand its biological underpinnings.
• The study suggests that mitochondrial health in the hippocampus may play a central role in opioid-associated POCD in aged subjects — though human studies are needed to confirm this.
• Therapeutic strategies targeting mitochondrial function, including peptides like SS-31, show early promise in preclinical models and may represent a future direction for clinical investigation.
• Neuroinflammation appears to be an early driver of long-term cognitive changes, suggesting that the perioperative window may be a critical time for protective interventions.
• Elevated neurofilament light chain (Nf-L) in blood was identified as a marker of ongoing axonal stress — a biomarker that may eventually help clinicians monitor patients at risk for POCD.

None of these findings should be interpreted as medical advice, and no patient should alter their surgical care or pain management plan based on preclinical research alone. The value of this study lies in the scientific directions it opens, not in providing immediate clinical guidance.

Conclusion

The 2026 study by Muscat, Deems, Alvarez, and colleagues represents a meaningful step forward in understanding why surgery and opioids can leave a lasting mark on the aging brain. By pinpointing hippocampal mitochondrial dysfunction as a central mechanism — and demonstrating that a mitochondria-targeting peptide can restore memory function even weeks after injury — the research suggests that POCD may be more biologically reversible than previously assumed, provided the right therapeutic targets are engaged at the right time.

As the science continues to evolve, staying informed and working with a knowledgeable, integrative medical provider will be essential for older adults navigating surgical care. To find a qualified physician who stays current with emerging research in peptide science and cognitive health, visit peptideassociation.org/find-a-doctor.

---

Medical Disclaimer: This article is intended for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. The research discussed involves animal models; findings may not directly translate to human physiology or clinical outcomes. Always consult a qualified, licensed healthcare provider before making any decisions about your medical care, surgical planning, or use of any therapeutic agent.

---

AMA Citation: Muscat SM, Deems NP, Alvarez BD, et al. Disruption of hippocampal mitochondrial function underlies opioid-induced postoperative cognitive dysfunction in aged rats. Brain Behav Immun. 2026;(August). doi:10.1016/j.bbi.2026.106942. PMID: 42546889.